生物吸收性支架在冠状动脉慢性全闭症中的使用:长期单中心随访研究
Dace Sondore1,2, Ieva Briede1,2, Matiss Linde1,2
1Pauls Stradins Clinical University Hospital, LV-1002 Riga, Latvia.
Medicina (Kaunas, Lithuania)
|August 29, 2024
概括
生物可吸收支架 (BRS) 为慢性全闭症 (CTO) 中的穿皮冠状动脉干预 (PCI) 提供了一种安全有效的替代方案,避免需要广泛的金属支架,并保持长期冠状动脉通透性.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
- 生物材料科学 生物材料科学
背景情况:
- 经皮冠状动脉干预 (PCI) 治疗慢性全闭症 (CTO) 通常需要长时间的支架植入.
- 使用多种药物排泄支架 (DES) 可以导致"全金属外套"效应.
- 生物吸收性支架 (BRS) 是一种潜在的替代方案,可以最大限度地降低金属植入物负担.
研究的目的:
- 在CTO PCI中评估BRS的长期安全性和有效性.
- 评估BRS的可行性,以避免在CTO中进行广泛的金属支架.
- 为了确定在CTO中BRS植入后的长期穿透率.
主要方法:
- 未来的,单中心的,纵向的案例研究.
- 包括34名接受PCI的患者为CTO与BRS和/或DES.
- 使用定量冠状动脉血管学 (QCA) 和血管内超声波进行评估.
主要成果:
- 随访时间中位数为5.6年.
- 目标血管的重新封闭发生在5.9%的患者中.
- 在35.3%的患者中,需要针对性损伤再血管化 (TLR),TLR的平均时间为62.5个月.
结论:
- 在CTO中,BRS是PCI的安全和可行的选择.
- 通过BRS的植入,可以避免在CTO中长段支架.
- 在CTO患者中,BRS可以实现长期的冠状动脉通透性.
相关概念视频
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...


